secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K/A
Filed at:   2022-10-14T23:59:59+00:00
Accession:  0001140361-22-037226
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.25
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata files audited FY2020-2021 financials of acquired Cend Therapeutics
-------------------------------------------------------------------------

- Audited financial statements of Cend for FY2020 and FY2021 filed as Exhibit 99.1.
- Consent of independent auditor WithumSmith+Brown, PC filed as Exhibit 23.1.
- This amendment fulfills the remaining financial statement requirements for the September 2022 merger.
- No other changes were made to the initial Form 8-K reporting the merger completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000114036122037226/0001140361-22-037226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000114036122037226/brhc10042873_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-037226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer